Based on JPMorgan, Kenvue is well positioned to speed up growth after separating from parent company Johnson & Johnson. After being spun off in early May, Kenvue is the world’s largest consumer health company. The corporate has household names resembling Neutrogena, Tylenol, Aveeno and Zyrtec – a complete of 10 brands with sales in excess of $400 million. Kenvue also has over 37 regional brands. Analyst Andrea Teixeira initiated the coverage of the stock with an obese rating. Its price goal of $29 is up greater than 10% from the previous close. “As an independent company, we consider Kenvue’s board and management will likely be more focused and accountable for the corporate’s growth and profitability after the separation that began in 2019 and thru mergers and acquisitions,” Teixeira wrote in a Monday note. “We consider KVUE is uniquely positioned to capitalize on consumer megatrends (self-care, aging).” Teixeira added that Kenvue continues to be “US-centric”, giving it the chance to regain its share and “uplift and shift” some of its brands in overseas markets. JPMorgan believes Kenvue continues to post a pretty valuation, despite a spike since its May 3 IPO, which was priced at $22 a share. By Friday’s close, the stock traded at $26.30. “As KVUE builds on its track record as a public company (if our solid quarters ahead estimate materializes) and after potentially distributing the shares JNJ holds to existing JNJ shareholders, we consider KVUE should trade with top of the range multinationals which might be characterised by defensive sales, complex growth and solid free money flow conversion,” said Teixeira. — Michael Bloom of CNBC contributed to this report.